Shanghai

David Ferguson: An Expert Decoding China's Stories

Retrieved on: 
Wednesday, December 1, 2021
People, Science and Technology Daily, News, Special Book Award of China, Book, Foreign language, China International Publishing Group, Shanghai, Riot, Goal, Technology, Pleasure, Twitter, Research, Friendship Award (China), Publishing, Attitude, Olympic Games, Translation, Multimedia, Republic, 2008 Sichuan earthquake, Film, Entertainment, Public relations

Ferguson summed up his feelings as "an honor, a surprise, a pleasure" when presented with the Friendship Award.

Key Points: 
  • Ferguson summed up his feelings as "an honor, a surprise, a pleasure" when presented with the Friendship Award.
  • "I could see in the documentary and video evidence of what was going on in Lhasa.
  • However, the stories that the Western media showed were just completely different and had nothing to do with the truth.
  • Because somebody should at least try to present a more honest version of what is happening in China," he said.

“Vive la Differénce,” Philippe Starck’s White Tulip Collection for Duravit

Retrieved on: 
Tuesday, November 30, 2021
Black, Language, Relaxation, Wind, Time, Black Forest, Duravit, White Tulip, Solution, USA, Restaurant, GLOBE, Collection, Water, Architecture, The Chartered Institute of Ergonomics and Human Factors, Philosophy, Glass, Quality of life, Flowers, Interior design

Atlanta, GA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Duravit USA is pleased to introduce White Tulip, a new holistic bathroom collection designed by Philippe Starck.

Key Points: 
  • Atlanta, GA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Duravit USA is pleased to introduce White Tulip, a new holistic bathroom collection designed by Philippe Starck.
  • We are thrilled to introduce White Tulip to our market, comments Tim Schroeder, President of Duravit North America.
  • White Tulip offers our audience a complete bathroom collection with a simultaneously new and nostalgic sense of design.
  • Philippe Starck brings three beautiful freestanding bathtub designs to market within his White Tulip collection.

Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer

Retrieved on: 
Tuesday, November 30, 2021
PARP, Company, Woman, NMPA, PFS, New Drug Application, Risk, GLOBE, Gynecologic Oncology (journal), Cholangiocarcinoma, Â, ADP, Drug development, Department, Peritonitis, Private Securities Litigation Reform Act, Ovarian cancer, PRIME, Shanda, Peking Union Medical College, Death, Research, Degenerative disease, GlaxoSmithKline, HIV disease progression rates, Hospital, Infection, U.S. Securities and Exchange Commission, Coronavirus, Niraparib, Forward-looking statement, NORA, Platelet, All-comers track meet, Health, Clinical trial, Progression-free survival, Adult, NASDAQ, Medicine, NRDL, Maintenance, PRIMA, Patient, Cancer, National Cancer Center, Safety, Fibroadenoma, SAN, COVID-19, Endometrial cancer, Liu v. Securities and Exchange Commission, Disease, Medical imaging, Pharmaceutical industry, Birth control, Online shopping

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Phase 3 PRIME study of ZEJULA (niraparib) as maintenance therapy met its primary endpoint. ZEJULA demonstrated a statistically significant and clinically meaningful progression-free survival (PFS) benefit with a tolerable safety profile in Chinese patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) following a response to platinum-based chemotherapy, regardless of biomarker status.

Key Points: 
  • Importantly, the PRIME study further underscores the status of ZEJULA as the first and only PARP inhibitor approved globally, including in China, as monotherapy for all-comer patients in the first-line maintenance treatment settings.
  • The study evaluated the efficacy of ZEJULA as a maintenance treatment, with the primary endpoint of PFS as assessed by blinded independent central review.
  • While platinum-based chemotherapy is effective at inducing an initial response in ovarian cancer, the disease will recur in the majority of women.
  • A Phase 1 pharmacokinetic (PK) study of ZEJULA was conducted in Chinese patients with ovarian cancer.

Smart Share Global Limited Announces Third Quarter 2021 Results

Retrieved on: 
Tuesday, November 30, 2021

SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Smart Share Global Limited (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter ended September 30, 2021.

Key Points: 

GDS Releases Inaugural ESG Report and Sets Carbon Neutral Target

Retrieved on: 
Tuesday, November 30, 2021
CGN, Carbon, Biophysical environment, Environment, Industry, Social Security Government Pension Offset, Company, Social, ESG, Female, Telecommunication, GLOBE, GDS, Efficiency, Electricity, Internet, NASDAQ, Renewable energy

SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GDS Holdings Limited(GDS Holdings, GDS or the Company)(NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers inChina, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report.

Key Points: 
  • SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GDS Holdings Limited(GDS Holdings, GDS or the Company)(NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers inChina, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report.
  • We have set a target for GDS to be carbon neutral by 2030 and we are on track to meet this goal.
  • Our inaugural ESG report demonstrates that were serious about enhancing transparency and taking initiative.
  • To view the report in full, please visit the ESG section on the GDS corporate website or access the report at:
    GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698) is a leading developer and operator of high-performance data centers in China.

Baozun Announces US$50 Million Share Repurchase Program in addition to the Completed US$125 Million Shares Repurchase Program

Retrieved on: 
Tuesday, November 30, 2021
Technology, Industry, HKEX, Private Securities Litigation Reform Act, Forward-looking statement, Company, Banja Luka Stock Exchange, Solution, Omnichannel, Goal, U.S. Securities and Exchange Commission, Policy, American, Nasdaq, GLOBE, Terminology, Stock exchange, Share repurchase, Risk management

The Companys board of directors will review the share repurchase program periodically and may authorize adjustment of its terms and size.

Key Points: 
  • The Companys board of directors will review the share repurchase program periodically and may authorize adjustment of its terms and size.
  • The Company plans to fund repurchases from its existing cash balance.
  • Statements that are not historical facts, including statements about the Companys strategies and goals, are or contain forward-looking statements.
  • Baozun Inc. is the leader and a pioneer in the brand e-commerce service industry in China.

Hywin Wealth and VP Bank to Launch Joint Report on Private Markets in Asia

Retrieved on: 
Tuesday, November 30, 2021
HYW, Private Securities Litigation Reform Act, Forward-looking statement, Company, Partnership, SEC, COVID-19, Woman, Female, Research, GLOBE, VP Bank, Terminology, NASDAQ, McKinsey & Company, Financial services, Tutoring

SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hywin Holdings Ltd. ("Hywin Wealth", Hywin, or the "Company") (NASDAQ: HYW), a leading independent wealth management service provider in China, today announced that it will launch a joint report on private markets in Asia early next year, together with Liechtenstein-based VP Bank Ltd, and WealthBriefingAsia.

Key Points: 
  • SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hywin Holdings Ltd. ("Hywin Wealth", Hywin, or the "Company") (NASDAQ: HYW), a leading independent wealth management service provider in China, today announced that it will launch a joint report on private markets in Asia early next year, together with Liechtenstein-based VP Bank Ltd, and WealthBriefingAsia.
  • Despite the global COVID-19 pandemic, global AUM in the private markets rose 5.2% to an all-time high of US$7.4 trillion in the second half of 2020, according to a report from McKinsey .
  • And yet, investors in Asia tend to face challenges unique to the region, such as lack of access to and understanding of the private markets.
  • This report is a continuation of the research partnership between Hywin Wealth, VP Bank and WealthBriefingAsia, who collaborated in 2020 to launch the report: Winning Women in Asia-Pacific: Insights for wealth managers direct from female clients .

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

Retrieved on: 
Tuesday, November 30, 2021
Lung, World Health Organization, HKEX, Esophagus, Esophageal cancer, Kidney, New Drug Application, Cisplatin, Hope, Stomach, GLOBE, Blas, Marketing, NDA, National Medical Products Administration, United, NPC, World, Immunotherapy, Breakthrough therapy, Liver, PD-L1, PD-L2, Head, Shanda, R & D, Microbiology, Bamlanivimab, Mucosal melanoma, Research, Nature Medicine, Sun Yat-sen University Cancer Center, PD-1, Infection, Review, LBA, SSE, Breast, Progression-free survival, Squamous cell carcinoma, Therapy, Survival, Fast Track, Society, FDA, EUA, Patient, Skin, Safety, Eli Lilly, Severe acute respiratory syndrome coronavirus 2, Autoimmunity, BLA, Ligand, Pharynx, Sun, Bamlanivimab/etesevimab, NMPA, American Society of Clinical Oncology, ASCO, Pharmaceutical industry

In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma.

Key Points: 
  • In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma.
  • In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy.
  • This study is the worlds largest Phase III clinical study for a checkpoint inhibitor in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).